Investegate |Angle PLC Announcements | Angle PLC: Parsortix demonstrates high capture rate of CTCs
CANCER-ID was a European consortium funded by the Innovative Medicines Initiative (IMI) aimed at the establishment of standard protocols for and clinical validation of blood-based biomarkers. It brought together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs), diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of "liquid biopsies". About ANGLE plc ...
Source: investegate.co.uk